top of page
Supported projects
Yomi Pharma
Exploits the natural properties of the sortilin protein to develop therapeutic solutions targeting EGFR-positive tumours. Their first innovation is a sortilin-derived peptide designed to treat lung adenocarcinoma.
PSCC's entrance
November 2024
Localization
FR - Nouvelle Aquitaine
Modality
Targeted therapy
Development status
Biotech - Lead optimization
Award(s)
iLAB
bottom of page